department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Cogent Biosciences, Inc. ($COGT) · pharmadog

PUBLIC COMPANY

$COGTCogent Biosciences, Inc.

Waltham, MA, USupdated 2h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

3

marketed

1

phase 3

0

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(3)

pipeline depth3 products

1Preclinical1Marketed1pre_registration

Tumor necrosis factor

Unspecified Cancer

pre_registration

Gastrointestinal Stromal Tumor (GIST)

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

Cogent Biosciences, Inc. earnings

Cogent Biosciences, Inc.

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Cogent Biosciences, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$COGT

SEC CIK

0001622229

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase1A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumorsrecruitingn=90
phase2(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosisrecruitingn=140
phase2A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumorsactive not recruitingn=110
—Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumorsavailable
—Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosisavailable
phase2(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosisactive not recruitingn=237
phase1A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumorsrecruitingn=100
phase3(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumorsactive not recruitingn=442

more trials →

Data sources

SEC EDGAR · openFDA

last refreshed 4m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$COGT39.06+0.96%

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 31, 26SELLFairmount Funds Management LLC· 7,000,000 sh @ $34.66−$242.62M↗

routine RSU / option mechanics (3)

Apr 1, 26grantFerrante Karen Jean · director686 sh
Mar 31, 26cFairmount Funds Management LLC · 7,000,000 sh
Mar 31, 26cFairmount Funds Management LLC · 28,000 sh

$COGT39.06+0.96%